Neurocrine Biosciences (NBIX): Reiterating Overweight Ahead Of ASRM - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow slide after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil heads for weekly gain as US-Iran fighting resumes; diesel hits record high
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Needham & Company Starts Neurocrine Bio. (NBIX) at Buy
October 18, 2016 7:01 AM EDTNeedham & Company initiates coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Buy rating and a price target of $62.00.
Analyst Alan Carr commented, "We are initiating coverage of Neurocrine with a BUY rating. Neurocrine announced positive results from a Phase 3 trial of Ingrezza in... More
